Suzhou Ribo Life Science Co., Ltd. (HKG:6938)
Hong Kong · Delayed Price · Currency is HKD 57.40
-0.30 (-0.52%)
Sep 10, 2026, 11:37 AM HKT
Suzhou Ribo Life Science Revenue
Suzhou Ribo Life Science had revenue of 419.74M CNY in the half year ending June 30, 2026, with 533.04% growth. This brings the company's revenue in the last twelve months to 464.43M, up 157.83% year-over-year. In the year 2025, Suzhou Ribo Life Science had annual revenue of 148.51M with 4.12% growth.
Revenue (ttm)
464.43M CNY
Revenue Growth
+157.83%
P/S Ratio
18.35
Revenue / Employee
1.03M CNY
Employees
453
Market Cap
9.84B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 148.51M | 5.88M | 4.12% |
| Dec 31, 2024 | 142.63M | 142.58M | 324,052.27% |
| Dec 31, 2023 | 44.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Everest Medicines | 2.78B |
| Lepu Biopharma | 1.14B |
| Ascentage Pharma Group International | 741.90M |
| Alphamab Oncology | 598.06M |
| CStone Pharmaceuticals | 490.92M |
| Nanjing Leads Biolabs | 246.16M |
| GenFleet Therapeutics (Shanghai) | 144.96M |
| Ascletis Pharma | 1.09M |
Suzhou Ribo Life Science News
- 13 days ago - Suzhou Ribo Life Science Earnings release: H1 2026 - Filings
- 5 months ago - Suzhou Ribo Life Science Earnings release: H2 2025 - Filings
- 5 months ago - Suzhou Ribo Life Science Annual report: H2 2025 - Filings